Xencor preliminary year-end cash falls to $611 million from $706.7 million
Xencor preliminarily estimates cash, cash equivalents and marketable debt securities of approximately $611 million as of December 31, 2025, down from $706.7 million a year earlier. The company says it expects cash to fund research and development programs and operations through 2028, but the figures are unaudited and may change after year-end closing and audit procedures.
Key points
- Preliminary cash, cash equivalents and marketable debt securities: approximately $611 million as of December 31, 2025, versus $706.7 million as of December 31, 2024
- Company expects cash to fund research and development and operations through 2028, based on current operating plans
- Figures are unaudited and not reviewed by the independent auditor; actual results may differ
- Press release also outlines 2026 milestones, including a Phase 1 study start for XmAb412 in 2H26 and clinical data updates across several programs
The filing
Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.